- Lobbying
- Lobbying by Amarin Pharma Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
William Wichterman | Special Ass't to President Bush and Deputy Dir. Deputy Staff Director (2007-2008); House of Comm. on Appropriations, Professional Staff |
" " | OPL Policy advisor, Senate Majority Leader Bill Frist Chief of Staff, Rep. Joseph Pitts Chief of Staff, House Rules Committee, Staff Director (2009-2010); House Rules Committee, Rep. Select Committee on Voting Irregularities, General Counsel, detailed (9/07-9/08); House Comm. on Appropriations, Professional Staff (2006-2007); House of Parliamentarian. Director (2007-2008); House Rep. Select Committee on Voting Irregularities, General Counsel, detailed (9/07-9/08); House Committee on Appropriations, Professional Staff (2006-2007); House Office of the Parliamentarian: Associate (2005); OPL Policy Advisor, Senate Majority Leader Deputy Staff Director (2007-2008); House of Rep. Select Committee on Voting Irregulatories, (2006-2007); House Parliamentarian. 2010); House Rules Committee, Deputy Staff Counsel, Detailed (9/07-9/08); House Comm. 2007); House Office of the Parliamentarian: Assoc. (2005); (Assistant 1991-2005); Clerk |
Muftiah McCartin | House Rules Committee, Staff Director (2009- 2010); House Rules Committee, Deputy Staff (Assistant 1991-2005); Clerk |
Joan Kutcher | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Q3 Report
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: PDUFA: FDA special protocol assessment agreement process..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate